Brief: Csl Reports Positive Top-Line Phase 3B Results Supporting Planned Expanded Pediatric Filing For Andembry® (Garadacimab-Gxii) In Children With Hereditary Angioedema (Hae)
27/07/2026 14:01
BRIEF-Csl Reports Positive Top-Line Phase 3B Results Supporting Planned Expanded Pediatric Filing For Andembry® (Garadacimab-Gxii) In Children With Hereditary Angioedema (Hae) July 27 (Reuters) - CSL Ltd CSL.AX:
CSL REPORTS POSITIVE TOP-LINE PHASE 3B RESULTS SUPPORTING PLANNED EXPANDED PEDIATRIC FILING FOR ANDEMBRY® (GARADACIMAB-GXII) IN CHILDREN WITH HEREDITARY ANGIOEDEMA (HAE)
CSL - REPORTS POSITIVE PHASE 3B RESULTS FOR ANDEMBRY IN CHILDREN WITH HEREDITARY ANGIOEDEMA
CSL - ANDEMBRY SHOWED FAVORABLE SAFETY; MAJORITY REMAINED ATTACK-FREE DURING 12-MONTH TREATMENT PERIOD
CSL - TO SUBMIT FILINGS FOR EXPANDED PEDIATRIC INDICATION FOR ANDEMBRY IN FIRST HALF OF FISCAL YEAR
Source text: ID:nPn5nC4kXa
Further company coverage: CSL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CSL
See all newsCiti says CSL's CEO pick brings key strengths
Australia's CSL names GSK executive Waterhouse as next CEO (updated)
Brief: CSL Limited Appoints Deborah Waterhouse As CEO And Managing Director
Australia's CSL appoints Deborah Waterhouse as CEO
Early US flu season, current strain may signal risk for younger people; doctors urge shots